Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 6, Issue 2, 2024

Study on the Protective Effect and Mechanism of BaiheWuyao Decoction on Non-alcoholic Fatty Liver Disease Based on Network Pharmacology

Download as PDF

DOI: 10.23977/medcm.2024.060202 | Downloads: 0 | Views: 68

Author(s)

Tiantian Ban 1, Yue Guo 1, Jiaqi Li 1, Shenghe Jiang 1, Chenshuan Qin 2, Junpeng Shuai 1, Dan Li 1, Siqi Liu 2

Affiliation(s)

1 Department of Pharmacy, North China University of Science and Technology, Tangshan, 063210, China
2 Department of Basic Medicine, North China University of Science and Technology, Tangshan, 063210, China

Corresponding Author

Tiantian Ban

ABSTRACT

To explore the protective effect and mechanism of Baihe Wuyao Decoction (BWD) on non-alcoholic fatty liver disease (NAFLD) by using network pharmacology and molecular docking technology. The main active ingredients of Baihe and Wuyao were screened through the TCM Systematic Pharmacology Database Platform (TCMSP) database, The Swiss Target Prediction database, UniProt database and PharmMapper database screened the gene targets of Baihe and Wuyao; The GeneCards database and the OMIM database were used to obtain the relevant gene targets for NAFLD; Using Venn2. 1 Acquisition of drug-disease common targets; The String 11.5 database was used to construct a protein-protein interaction (PPI) network for the treatment of NAFLD in Baihe Wuyao Decoction to screen the core targets; Based on the Metascape gene function annotation analysis tool, the gene ontology (GO) and Kyoto Encyclopedia of Genomes (KEGG) pathway enrichment analysis of the intersection targets were performed; The active ingredient-drug target and active ingredient-target-pathway interaction network were constructed using Cytoscape 3.7.2 software to obtain the core active ingredient; AutoDockTools-1.5.6 software was used to select six of the top 30 genes in the PPI network and five core active components for molecular docking to verify the binding performance, and visualized with PyMOL. A total of 7 active ingredients and 286 related targets of Baihe were obtained, a total of 509 targets were collected after removing duplicate targets and gene annotation. A total of 1864 NAFLD-related targets were screened through the GeneCards database and the OMIN database,a total of 78 intersecting targets were obtained through Venn diagrams, and there were 78 intersecting targets between Baihe Wuyao Decoction and NAFLD, The main active ingredients involved are β-sitosterol, quercetin, isohexaturonic acid, norisopordine, 6,7-dimethoxy-2-(phenyethyl) chromone among others. The core targets are PPAR (peroxisome proliferation activation receptor α), JUN (chromosomal gene), NOS3 (nitric oxide synthase), ESR1 (estrogen receptor), etc. KEGG pathway enrichment analysis showed that PPAR signaling pathway and endocrine resistance may be the key signaling pathways in the treatment of non-alcoholic fatty liver disease (NAFLD) by Baihe Wuyao Decoction. The molecular docking results showed that the binding energy of the five core pharmaceutical active ingredients and the corresponding key targets was less than -4.0kJ/mol. Among them, β-sitosterol and 3DMC could be well combined with six core targets, and it was predicted that they were important active ingredients for the intervention of non-alcoholic fatty liver disease in Baihe Wuyao Decoctionn. BWD can protect NAFLD through multiple targets and pathways,  The core active ingredients of BWD includes β-sitosterol, quercetin, isohaipineic acid, norisopordine, 6,7-dimethoxy-2-(phenylethyl) chromoneand 3DMC, which can act on multiple key targets such as AKT1, PPARA, BCL2, and ESR1, regulate PPAR signaling pathway, endocrine resistance and other signaling pathways. The mechanism of BWD protects againstNAFLDisrelated to the improvement of glucose-lipid metabolism and insulin resistance, as well as anti-inflammatory effects and enhancing autophagy functions.

KEYWORDS

BaiheWuyao decoction, non-alcoholic fatty liver disease, molecular docking, network pharmacology

CITE THIS PAPER

Tiantian Ban, Yue Guo, Jiaqi Li, Shenghe Jiang, Chenshuan Qin, Junpeng Shuai, Dan Li, Siqi Liu, Study on the Protective Effect and Mechanism of BaiheWuyao Decoction on Non-alcoholic Fatty Liver Disease Based on Network Pharmacology. MEDS Chinese Medicine (2024) Vol. 6: 10-23. DOI: http://dx.doi.org/10.23977/medcm.2024.060202.

REFERENCES

[1] Menganslimu, Liang Jie, Jin Rong, et al. Research progress of Mongolian medicine in treating liver disease[J]. Chinese Journal of Ethnic Medicine, 2018, 24(8):60-63. 
[2] Cai Lianying, Wang Wenjuan, Liang Yunxiao, et al. Research progress on the correlation between metabolism-related fatty liver disease and metabolic syndrome[J]. China Clinical New Medicine, 2021, 14(7):730-734. 
[3] JANG R, KANG D, SINN H, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study[J]. Scientific Reports, 2021, 8(1):1-9. 
[4] ESTES C, ANSTEE Q M, ARIAS-LOSTE M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016- 2030[J]. Journal of Hepatology, 2018, 69(4):896-904. 
[5] Drescher K, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)[J]. Cells, 2019, 8(8):1-23. 
[6] Zhong L P , Li J , Wang F Z ,et al.Protective effect and underlying mechanism of cordycepin on non-alcoholic fatty liver in ob/ob mice[J].Acta Pharmaceutica Sinica, 2017, 52(1):106-112.DOI:10.16438/j.0513-4870.2016-0886.
[7] Zhang Huifang. Research on chemical composition and pharmacological mechanism of traditional Chinese medicine lily [D]. Nanjing University of Traditional Chinese Medicine, 2007. 
[8] Liu Kuanhui. Research on the immune-enhancing activity of polysaccharide-selenated polysaccharide complex [D]. Nanjing Agricultural University, 2017. 
[9] Wang W, Chen Y, Hu Y, et al. Effects of Linderae radix extracts on a rat model of alcoholic liver injury[J]. Experimental and Therapeutic Medicine, 2016, 11(6):2185-2192. 
[10] Xing Mengyu, Tian Chongmei, Xia Daozong. Progress in the study of chemical composition and pharmacological effects of Wu Yao[J]. Natural Products Research and Development, 2017, 29(12):2147-2151. 
[11] YANG J J, CHEN Y, GUO L, et al. Chemical constituents from the roots of Lindera aggregata and their biological activities[J]. Journal of Natural Medicines, 2020, 74(2):441-447
[12] Chen SJ. Protective effects of sesquiterpene lactone derivatives on pancreatic islet cells in db/db mice [D]. Southern Medical University, 2015. 
[13] Luo Y, Liu M, Xia Y, et al. Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice[J]. Phytomedicine, 2010, 17(10):726-731. 
[14] Luo Y B, Liu M, Yao X J, et al. Total alkaloids from Radix Linderae prevent the production ofinflammatory mediators in lipopolysaccharide-stimulated RAW 264. 7 cells by suppressing NF kappa B and MAPKs activation[J]. Cytokine, 2009, 46(1):104-110. 
[15] Barabasi A L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease[J]. Nature Reviews Genetics, 2011, 12(1):56-68. 
[16] Li S, Wu J, Zhang Q. Constructing biological networks through combined literature mining and microarray analysis: a LMMA approach[J]. Bioinformatics, 2006, 22(17):2143-2150. 
[17] Zhang Shengsheng, Li Junxiang. Expert consensus opinion on Chinese medicine diagnosis and treatment of nonalcoholic fatty liver disease(2017)[J]. Journal of Clinical Hepatobiliary Diseases, 2017, 33(12):2270-2274. 
[18] Zhu D, Sun Tingting, Chen Lanyu et al. Traditional Chinese medicine understanding of fatty liver disease[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2020, 22(05):70-73. DOI:10. 13194/j. issn. 1673-842x. 2020. 05. 017. 
[19] Alia Kaiser, Fan Xingliang. Progress of clinical research on the treatment of non-alcoholic fatty liver disease by traditional Chinese medicine[J]. Hebei Traditional Chinese Medicine, 2024, 46 (01): 162-166. 
[20] Wang Rui, Ban Tiantian, Xue Lihui, Feng Xinyi, Guo Jiyuan, Li Jiaqi, Jiang Shenghe, Han Xiaolei, Hu Baofeng, Zhang Wenli, Wu Naijun, Li Shuang, Qi Yajuan. Enhancement of hepatic autophagy through inhibition of mTOR by Lily and Wu Yao Tang improves non-alcoholic fatty liver disease[J]. Chinese Journal of Experimental Formulas, 2024, 30 (07): 66-77. 
[21] ZHOU Haiyue, TANG Wei, JIANG Jing, SONG Lihua. In vitro study on the effects of β-sitosterol and soy sterol on nonalcoholic fatty liver[J]. Journal of Nutrition, 2016, 38(05):456-461. 
[22] FENG Yali, LI Hao, LIU Juan, et al. Progress of Que research [J]. Chinese Journal of Traditional Chinese Medicine, 2021, 46(20):5185-5193
[23] Yang D Y, Wang T C, Long M A, et al. Quercetin:its main pharmacological activity and potential application in clinical medicine[J]. Oxid Med Cell Longev, 2020, 2020:1-13 
[24] ZHAO X T, WANG J, DENG Y, et al. Quercetin as a pro⁃ tective agent for liver diseases:a comprehensive descrip⁃ tive review of the molecular mechanism[J]. Phytother Res, 2021, 35(9):4727-4747
[25] Biao T , Chang-Qing D .Action mechanism of Jiangzhi Ligan Decoction in treatment of non-alcoholic fatty liver disease based on network pharmacology[J].Chinese Traditional and Herbal Drugs, 2018.DOI:10.7501/j.issn.0253-2670.2018.15.005. 
[26] Luo Y B, Liu M, Dai Y, et al. Norisoboldine inhibits the production of pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW 264. 7 cells by downregulating the activation of MAPKs but not NF-κB [J]. Inflammation, 2010, 33( 6) : 389. 
[27] YANG Junshan, WANG Yulan, SU Yalun. Studies on the chemical composition of domestic incense[J]. Journal of Pharmacy, 1990, 25(3):186-190. 
[28] Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China, Vol. 1 [M]. Beijing: Medicine Science and Technology Press of China, 2020: 192–193. 
[29] Ibrahim S R M, Mohamed G A. Natural occurring 2-(2-phenylethyl) chromones, structure elucidation and biological activities [J]. Nat Prod Res, 2015, 29(16): 1489–1520. doi: 10. 1080/14786419. 2014. 991323
[30] Liu Zhu, Wang Jiawei, Yan Jing et al. Research progress of Chinese medicine regulating PI3K/Akt pathway to intervene in sepsis[J/OL]. Chinese Journal of Experimental Formulary, 1-10[2024-03-26]. https://doi. org/10. 13422/j. cnki. syfjx. 20240611. 
[31] Cha Zhenwei. Changes of protein kinase B expression in the liver of rats with nonalcoholic fatty liver disease and the study of N-acetylcysteine and melatonin intervention[D]. Anhui Medical University, 2008. 
[32] Cao Y J , Li H Z , Zhao J ,et al.Mechanical Study of Jian-Gan-Xiao-Zhi Decoction on Nonalcoholic Fatty Liver Disease Based on Integrated Network Pharmacology and Untargeted Metabolomics[J].Evidence-based complementary and alternative medicine: eCAM, 2022. 
[33] KRYCER JR, BROWN A J. Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis [J]. The Journal of Biological Chemistry, 2011, 286:20637-20647. DOI:10. 1074/jbc. M111. 227082. 
[34] Zuehlke AD, Beebe K, Neckers L, et al. Regulation and function of the human HSP90AA1 gene[J]. Gene, 2015; 570(1): 8-16. 
[35] Xin X, Wang WLi Y, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma[J]. JExp Clin Cancer Res, 2018;37(1):201. 
[36] Wheeler M C, Gekakis N. Hsp90 modulates PPARgamma activity in a mousemodel of nonalcoholic fatty liver disease[J]. J Lipid Res, 2014, 55(8):1702-1710. 
[37] FERRER M D, BUSQUETS-CORTEs C , CAPOX, et al. Cycloxygenase-2 inhibiors as a therapeutic target in inflammatory diseases[J]. Cur Med Chem, 2019, 26(18):3225-3241. 
[38] Yadav S K, Kambis T N, Kar S, et al. MMP9 mediates acutehyperglycemia-induced human cardiac stem cell death by upregulatingapoptosis and pyroptosis in vitro[J]. Cell Death Dis, 2020, 11(3):186. 
[39] Jones M E, Thorburn A W, Britt K L, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity [J]. Proceedings of the National Academy of Sciences, 2000, 97(23): 12735-12740. 
[40] Marx C E, Bradford D W, Hamer R M, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence [J]. Neuroscience, 2011, 191: 78-90. 
[41]Ping-Cuo,Suolang,Bao-Qing,et al.Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.[J].Journal of Ethnopharmacology, 2019.DOI:10.1016/j.jep.2019.03.006.
[42] Harley I T, Stankiewicz T E, Giles D A, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice[J]. Hepatology, 2014, 59(5): 1830-1839.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4258
Visits: 168945

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.